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Abstract
Background Management of diabetes in elderly subjects
is complex and careful management of glucose levels is of
particular importance in this population because of an
increased risk of diabetes-related complications and
hypoglycaemia.
Objective The aim of this study was to evaluate the
pharmacokinetic and pharmacodynamic properties of
insulin degludec (IDeg), a basal insulin with an ultra-long
duration of action, in elderly subjects with type 1 diabetes
compared with younger adults.
Methods This trial was a randomised, double-blind, two-
period, crossover trial conducted in a single centre and
included both inpatient and outpatient periods. Subjects
were men and women aged 18–35 years inclusive (younger
adult group) or C65 years (elderly group) with type 1
diabetes who received IDeg (0.4 U/kg) via subcutaneous
injection in the thigh once-daily for six days. Following
6-day dosing, a 26-hour euglycaemic glucose clamp
procedure was conducted to evaluate the steady-state
pharmacodynamic effects of IDeg. Blood samples were
taken for pharmacokinetic analysis up to 120 h post-dose.
Pharmacokinetic endpoints included the total exposure of
IDeg, ie the area under the IDeg serum concentration curve
during one dosing interval at steady state (AUCIDeg,s,SS)
(s = 0–24 h, equal to one dosing interval) and the maximum
IDeg serum concentration at steady state (Cmax,IDeg,SS).
Pharmacodynamic endpoints included the total glucose-
lowering effect of IDeg, ie the area under the glucose infu-
sion rate (GIR) curve at steady state (AUCGIR,s,SS), and the
maximum GIR at steady state (GIRmax,IDeg,SS).
Results Total exposure (AUCIDeg,s,SS) and maximum
concentration (Cmax,IDeg,SS) of IDeg were comparable
between elderly subjects and younger adults. Estimated
mean age group ratios (elderly/younger adult) for
AUCIDeg,s,SS and Cmax,IDeg,SS and corresponding two-sided
95 % confidence intervals (CIs) were 1.04 (95 % CI
0.73–1.47) and 1.02 (95 % CI 0.74–1.39), respectively.
Mean AUCIDeg,0–12h,SS/AUCIDeg,s,SS was 53 % in both
younger adult and elderly subjects, showing that in both
age groups IDeg exposure was evenly distributed across
the first and second 12 h of the 24-hour dosing interval.
No statistically significant differences were observed
between younger adult and elderly subjects with regard to
AUCGIR,s,SS (the primary endpoint of this study) and
GIRmax,IDeg,SS. Estimated mean age group ratios (elderly/
younger adult) for AUCGIR,s,SS and GIRmax,IDeg,SS and cor-
responding two-sided 95 % CIs were 0.78 (95 % CI 0.47–1.31)
and 0.80 (95 % CI 0.54–1.17), respectively. Duration of action
was beyond the clamp duration of 26 h in all subjects.
Conclusions The exposure of IDeg at steady state during
once-daily dosing was similar in younger adult and elderly
subjects. The glucose-lowering effect of IDeg was
numerically lower in elderly subjects compared with
younger adults, but no significant differences were
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observed between age groups. The ultra-long pharmaco-
kinetic and pharmacodynamic properties of IDeg observed
in younger adults were preserved in elderly subjects with
type 1 diabetes.
Clinical trials.gov number: NCT00964418
1 Introduction
Management of diabetes mellitus in elderly subjects is
complex. This heterogeneous patient population includes
individuals with diabetes who have few or no co-morbid-
ities, as well as others with additional chronic disorders,
differing degrees of diabetes-related co-morbidities or
cognitive impairment, and the physically frail [1]. Central
to effective diabetes management is ensuring optimal
control of blood glucose levels. This is of particular
importance in elderly subjects, who carry an increased risk
of developing long-term diabetes-related complications [1].
Furthermore, elderly subjects with advanced co-morbidi-
ties, polypharmacy and existing, advanced diabetes-related
complications are at an increased risk of insulin-induced
hypoglycaemia, associated with higher levels of morbidity
and mortality [2, 3]. This increased susceptibility is exac-
erbated by long-standing or established disease and hypo-
glycaemic unawareness, with individuals even more
vulnerable if living alone [4].
Insulin degludec (IDeg) is a new-generation basal
insulin developed for once-daily administration, which has
a distinct absorption mechanism. Upon subcutaneous (SC)
injection, IDeg forms long chains of multi-hexamers,
resulting in a soluble depot in the SC tissue from which
IDeg monomers gradually separate. This mechanism pro-
vides a slow and continuous absorption of IDeg into the
circulation, leading to flat, stable and ultra-long pharma-
cokinetic and pharmacodynamic profiles [5]. Moreover,
IDeg has four times less within-subject variability in glu-
cose-lowering effect compared with insulin glargine
(IGlar) [6]. This low level of variability in glucose-low-
ering effect suggests that IDeg may have utility in treating
elderly subjects, where the avoidance of hypoglycaemia is
of increased clinical importance.
Treatment of elderly subjects with diabetes is further
confounded by the limited clinical data currently available
in this subject population regarding the use of long-acting
insulin [2]. Therefore, studies evaluating the effects of
long-acting insulin in elderly subjects via a euglycaemic
clamp procedure would represent a valuable addition to the
clinical literature.
The primary objective of the present study was to
compare the pharmacokinetic and pharmacodynamic
properties of IDeg between elderly subjects and younger
adults with type 1 diabetes. Steady-state pharmacodynamic
properties of IDeg in elderly and younger adult subjects
were evaluated using a 26-h euglycaemic clamp procedure.
2 Materials and Methods
2.1 Study Design
This study was a single-centre (Department of Internal
Medicine, Division of Endocrinology and Metabolism,
Medical University of Graz, Austria), randomised, mul-
tiple-dose, double-blind, two-period, crossover trial con-
ducted in subjects with type 1 diabetes (Clinical trials.gov
number: NCT00964418). Before initiation, the trial was
reviewed and approved by the local independent ethics
committee according to local regulations. The trial was
performed in accordance with the Declaration of Helsinki
and its amendments in force at the initiation of the trial.
Subjects were informed of the risks and benefits of the
trial and that they could withdraw at any time for any
reason. Consent was obtained in writing before any trial-
related activities, and the investigator retained the consent
forms.
2.2 Subjects
Study participants were men and women aged 18–35 years
inclusive (younger adult group) or aged C65 years (elderly
group) with type 1 diabetes for C12 months, and a fasting
C-peptide level below 0.3 nmol/L. Other key inclusion
criteria for the trial included subjects who had been treated
with multiple daily insulin injections (or continuous SC
insulin infusion) for C12 months; a body mass index
(BMI) of 18.0–28.0 kg/m2 inclusive; a daily basal insulin
requirement of C0.2 IU/kg/day; a total daily insulin treat-
ment of \1.2 IU/kg/day; and a glycosylated haemoglobin
level of B10.0 %.
Exclusion criteria for study participation included
donation of blood or plasma in the past month or donations
of [500 mL within 3 months before screening; use of
systemic [oral or intravenous (IV)] corticosteroids, mono-
amine oxidase inhibitors, non-selective beta-blockers,
growth hormone, non-routine vitamins or herbal products;
use of thyroid hormones, unless this use had been stable
during the previous 3 months; smoking or the use of nic-
otine gum or transdermal nicotine patches during the
inpatient period; recurrent severe hypoglycaemia (more
than one severe hypoglycaemic event during the last
12 months); hypoglycaemic unawareness as judged by the
investigator; and hospitalisation for diabetic ketoacidosis
during the previous 6 months.
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2.3 Interventions and Pharmacokinetic Sampling
Following screening (Visit 1), subjects were randomly
allocated 1:1 to one of two predetermined treatment
sequences, each comprising two 6-day treatment periods
(Period 1, Visits 2–8; Period 2, Visits 9–15). Each treat-
ment period included once-daily SC dosing with 0.4 U/kg
of IDeg or IGlar, in a two-period crossover design. IGlar
was included primarily as a control in case differences
between age groups were observed for IDeg. As this was
not the case, only results from IDeg treatment are reported
herein. The two treatment periods were separated by a
washout period of 7–21 days, during which time subjects
resumed their normal insulin treatment.
IDeg [provided in 3-mL Penfill cartridges (100 U/mL)]
and IGlar [provided in 3-mL cartridges (100 U/mL)] were
administered once daily at approximately 8.00 pm via SC
injection into a lifted skin fold on the anterior surface of the
thigh using a syringe and needle. This region of injection is
commonly used for the injection of basal or long-acting
insulin preparations because of the slower absorption from
this site [7]. Doses were prepared by a study nurse not
otherwise involved in the trial, to maintain study blinding.
During treatment periods, additional control of blood glu-
cose levels was accomplished by bolus injections of insulin
aspart, which were administered into a lifted skin fold on
the lower abdominal wall and were supervised by the
investigator on a daily basis. As a general guidance to serve
as a basis for the supervision of the bolus insulin doses, the
daily mean pre-prandial plasma glucose values were to be
below or equal to 8.0 mmol/L (144 mg/dL). The last
injection of insulin aspart was no later than 10 h before
dosing on each clamp visit.
Initial dosing in each treatment period took place during
Visit 2 (Period 1) and Visit 9 (Period 2), respectively.
During these 48-h in-house visits, the first three once-daily
doses of IDeg or IGlar were administered at time points 0,
24 and 48 h. Subjects subsequently attended the clinic
daily for two further outpatient visits (Visits 3 and 4, and
Visits 10 and 11). Blood samples for assessment of phar-
macokinetic parameters were taken before the first dosing,
at frequent intervals within the first 24 h after the first
dosing (at intervals of 0.25–2 h) and immediately before
subsequent doses (Visits 3 and 4, and Visits 10 and 11).
The final dosing visit was an in-house visit (Visits 5 and
12) during which blood samples for steady-state pharma-
cokinetic assessment were taken regularly, both before (at
hourly intervals from 1 to 5 h pre-dose and at 15 min pre-
dose) and for 48 h after dosing (at intervals of 0.5–10 h).
Blood samples were also taken for plasma glucose analysis
every 5–30 min during this period up to 26 h post-dosing
and at 28, 38 and 48 h post-dosing. Subjects were dis-
charged 48 h after final dosing, and returned at 72, 96 and
120 h post-dose (Visits 6–8 and Visits 13–15) for blood
sampling for pharmacokinetic and plasma glucose analysis.
A final follow-up visit (Visit 16) was conducted 7–21 days
after the final dosing visit. The number of dosing days was
chosen to ensure that all subjects reached steady state
before a euglycaemic clamp was conducted.
2.4 Euglycaemic Glucose Clamp Procedure
The steady-state pharmacodynamic effects of IDeg were
evaluated using a 26-h euglycaemic clamp procedure
[target blood glucose 5.5 mmol/L, (100 mg/dL)], begin-
ning after final dosing, during Visit 5 (Period 1) and Visit
12 (Period 2). In brief, subjects fasted for at least 12 h
before dosing and the start of the 26-h clamp, and remained
fasted (with water ad libitum) and in a supine position until
the clamp procedure was complete. Approximately 5 h
before dosing a 3-h clamp run-in period was initiated,
during which subjects received a variable IV infusion of
human insulin (40 IU Actrapid, 100 IU/mL in 99.6 mL
saline) or glucose (10 %; Braun Infusomat FM, Melsun-
gen, Germany) to obtain the glucose clamp target level of
5.5 mmol/L (100 mg/dL). The target glucose clamp level
was maintained during a 2-h pre-dose clamp period leading
up to the time of last dose administration. When IV insulin
was used during the pre-dose clamp period, the rate of
insulin infusion was decreased gradually post-dosing
and terminated when glucose levels had declined by
approximately 0.3 mmol/L. A variable IV glucose infusion
was then initiated to maintain the clamp target level
[5.5 mmol/L, (100 mg/dL)]. The clamp was maintained for
26 h after dosing; however, the clamp procedure was ter-
minated early if plasma glucose levels consistently
exceeded 11.1 mmol/L (200 mg/dL) without any glucose
infusion in the previous 30 min.
2.5 Data and Statistical Analyses
The primary objective of the trial was to investigate the
pharmacodynamic effects of IDeg at steady state in elderly
subjects with type 1 diabetes versus younger adults with
type 1 diabetes. Secondary objectives for the two age
groups were to investigate the pharmacokinetic and phar-
macodynamic profiles, including the pharmacokinetic
exposure of IDeg at steady state, time to reach steady state
and the safety of IDeg. Pharmacokinetic endpoints for IDeg
included the area under the IDeg serum concentration–
time curve during one dosing interval at steady state
(AUCIDeg,s,SS) (s = 0–24 h), the maximum IDeg serum
concentration at steady state (Cmax,IDeg,SS) and the ratio
between AUCIDeg,0–12h,SS and AUCIDeg,s,SS (AUCI-
Deg,0–12h,SS/AUCIDeg,s,SS). The primary pharmacodynamic
endpoint for IDeg was the area under the glucose infusion
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rate (GIR) curve during one dosing interval at steady state
(AUCGIR,s,SS) (s = 0–24 h). Secondary pharmacodynamic
endpoints included GIRmax,IDeg,SS, the ratio between
AUCGIR,0–12h,SS and AUCGIR,s,SS (AUCGIR,0–12h,SS/AUC-
GIR,s,SS), and the duration of action of IDeg (time from dose
administration until the plasma glucose level increased to a
level consistently above 8.3 mmol/L [150 mg/dL], during
the glucose clamp procedure).
Safety assessments comprised adverse events (AEs),
including local injection-site reactions, laboratory
safety variables, physical examination, vital signs,
electrocardiogram (ECG) and hypoglycaemic episodes
(defined as ‘confirmed’ when they were either ‘severe’ as
defined by the American Diabetes Association [8] or verified
by a plasma glucose level of\3.1 mmol/L [56 mg/dL]).
IDeg serum concentrations were measured using a val-
idated IDeg sandwich enzyme-linked immunosorbent
assay. AUCIDeg,0–12h,SS and AUCIDeg,s,SS were calculated
as the area under the insulin concentration–time profile
using the linear trapezoidal method based on observed
values and actual measurement times. Missing values were
imputed using linear interpolation. Cmax,IDeg,SS was derived
from the individual concentration–time profiles.
AUCGIR,s,SS was derived from individual GIR profiles
and was calculated as the area under the smoothed GIR curve
using the linear trapezoidal technique on interpolated points.
GIRmax,IDeg,SS was derived from the smoothed GIR curve.
All analyses were conducted on the full analysis set.
Log-transformed AUCGIR,s,SS, GIRmax,IDeg,SS, AUCIDeg,s,SS
and Cmax,IDeg,SS values were analysed using an analysis of
variance method with age group (elderly/younger adult)





Subjects, n 14 13
Mean (SD) age, years 67.8 (3.2) 27.1 (4.9)
Sex, n (%)
Female 8 (57) 6 (46)
Male 6 (43) 7 (54)
Mean (SD) BMI, kg/m2 26.2 (1.5) 24.4 (2.3)
Mean (SD) duration of
diabetes, years
40.6 (16.3) 14.4 (6.1)
Mean (SD) HbA1c, % 7.7 (0.6) 7.8 (0.8)
Mean (SD) fasting
C-peptide, nmol/L
0.03 (0.07) 0.01 (0.01)
Mean (SD) eGFR 77.6 (14.8) 128.7 (14.7)
Insulin type at
screening, n (%)
Lispro 2 (14) 7 (54)
Aspart 11 (79) 3 (23)
Detemir 3 (21) 2 (15)
Glargine 7 (50) 3 (23)
Human insulin 2 (14) 5 (39)
Isophane insulin (NPH) 0 (0) 1 (8)
BMI body mass index, eGFR estimated glomerular filtration rate,
HbA1c glycosylated haemoglobin, NPH neutral protamine Hagedorn,
SD standard deviation
Fig. 1 Mean pharmacokinetic
profiles for insulin degludec at
steady state






AUCIDeg,s,SS, pmolh/L 85,673 82,727
Cmax,IDeg,SS, pmol/L 4481 4414
AUCIDeg,0–12h,SS/
AUCIDeg,s,SS, % (CV)
53 (5) 53 (5)
Elderly/younger adult (95 % CI)
AUCIDeg,s,SS 1.04 (0.73–1.47)
Cmax,IDeg,SS 1.02 (0.74–1.39)
Mean values are estimated least square means, except for the mean
ratio of AUCIDeg,0–12h,SS/AUCIDeg,s,SS, which was calculated and
summarised using descriptive statistics
AUCIDeg,s,SS area under the insulin degludec serum concentration
curve at steady state, CV coefficient of variation, CI confidence
interval, Cmax,IDeg,SS maximum insulin degludec serum concentration
at steady state
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and treatment period (Period 1/Period 2) as fixed factors.
Based on this model, age group means for absolute values
were estimated and mean age group ratios were estimated
together with two-sided 95 % confidence intervals (CIs).
Mean AUCIDeg,0–12h,SS/AUCIDeg,s,SS and AUCGIR,0–12h,SS/
AUCGIR,s,SS were calculated and summarised using




Forty-two subjects were screened, of whom 14 did not
meet the inclusion and/or exclusion criteria, and one
withdrew consent. Twenty-seven subjects were randomised
to treatment sequences (elderly subjects, n = 14; younger
adults, n = 13), and 26 subjects completed the trial (one
subject in the elderly group was withdrawn from the trial
because of a serious AE (detailed in Sect. 3.4).
All subjects were Caucasian, and the distribution of
male and female subjects and mean BMI in each group was
comparable (Table 1). Subjects had a mean [standard
deviation (SD)] age of 68 (3) years and 27 (5) years in the
elderly and younger adult groups, respectively, and a mean
duration of diabetes (SD) of 41 (16) years and 14 (6) years,
respectively (Table 1).
3.2 Steady-State Pharmacokinetics
Serum concentrations of IDeg were similar in elderly
subjects and younger adults, including mean IDeg con-
centration–time profiles at steady state (Fig. 1).
No statistically significant differences were observed in
AUCIDeg,s,SS and Cmax,IDeg,SS between elderly subjects and
younger adults (Table 2). Estimated mean age group ratios
(elderly/younger) for AUCIDeg,s,SS and Cmax,IDeg,SS and
corresponding two-sided 95 % CIs were 1.04 (95 % CI
0.73–1.47) and 1.02 (95 % CI 0.74–1.39), respectively.
Mean AUCIDeg,0–12h,SS/AUCIDeg,s,SS was 53 % in both
elderly subjects and younger adults (Table 2), suggesting
that in both age groups IDeg exposure was evenly dis-
tributed across the first and second 12 h of the 24-h dosing
interval.
Elderly subjects and younger adults reached clinical
steady state after 2–3 days of dosing, based on trough IDeg
serum concentrations; thus, concentrations increased only
over the first 2–3 days before reaching a plateau. Serum
IDeg concentrations at steady state were similar from day
to day (data not presented).
3.3 Steady-State Pharmacodynamics
No statistically significant differences were observed in
AUCGIR,s,SS (primary endpoint) and GIRmax,IDeg,SS
between elderly subjects and younger adults (Table 3).
Estimated mean age group ratios (elderly/younger adult)
for AUCGIR,s,SS and GIRmax,IDeg,SS and corresponding two-
sided 95 % CIs were 0.78 (95 % CI 0.47–1.31) and 0.80
(95 % CI 0.54–1.17), respectively. Mean AUCGIR,0–12h,SS/
AUCGIR,s,SS was 53 % in elderly subjects and 45 % in
younger subjects (Table 3), suggesting that in both age
groups the glucose-lowering effect of IDeg was close to
evenly distributed across the first and second 12 h of the
24-h dosing interval.
No subjects were withdrawn because of escape from
glucose clamp, and throughout the procedure plasma glu-
cose levels did not deviate considerably in any subject from
the clamp target of 5.5 mmol/L (100 mg/dL). There was no
difference in the coefficient of variation (CV) for the
observed glucose levels (0–24 h) between elderly and
younger adult subjects (CV 8.1 vs. 7.5 %).
To calculate the duration of action of IDeg, the end of
IDeg action was defined as the time at which the plasma
glucose level exceeded 8.3 mmol/L (150 mg/dL). The
plasma glucose level did not exceed 8.3 mmol/L for the
duration of the 26-h clamp procedure in any subject,
therefore the duration of action of IDeg was more than 26 h
in all elderly subjects and younger adults (data not
presented).
3.4 Safety
IDeg was generally well tolerated in this trial. Fifteen
treatment-emergent AEs were reported in eight (29.6 %)
subjects. Thirteen events occurred in six elderly subjects












53 (27) 45 (16)
Elderly/younger adult (95 % CI)
AUCGIR,s,SS 0.78 (0.47–1.31)
GIRmax,IDeg,SS 0.80 (0.54–1.17)
Mean values are estimated least square means, except for the mean
ratio of AUCGIR,0–12h,SS/AUCGIR,s,SS, which was calculated and
summarised using descriptive statistics
AUCGIR,s,SS area under the glucose infusion rate (GIR) curve at steady
state, CV coefficient of variation, CI confidence interval, GIRmax,-
IDeg,SS maximum GIR at steady state
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and two events occurred in two younger adult subjects; all
but one AE was mild. The most common AEs were
headache, with four events occurring in four subjects (three
elderly and one younger adult subject), and peripheral
oedema, with four events occurring in one elderly subject
(this repetitive event largely accounts for the overall
apparent disparity in AE numbers between the two age
groups). One injection-site reaction, defined as a burning
sensation that lasted for approximately 30 min and that was
mild in severity, was reported. A total of 74 treatment-
emergent confirmed hypoglycaemic episodes were reported
for 23 (85.2 %) subjects. Only one severe AE (hypogly-
caemic episode) following treatment with IDeg was
reported, in the elderly group. This event was considered
possibly related to IDeg and the subject was withdrawn
from the trial. The overall frequency of hypoglycaemia
reported in this trial may be artificially high, because all
subjects received a fixed dose of 0.4 U/kg for 6 consecutive
days, irrespective of their individual insulin requirements.
Thus, it is likely that the risk of hypoglycaemia was
increased for those subjects with a usual total daily basal
insulin dose of less than 0.4 U/kg. No clinically significant
changes in laboratory parameters, vital signs, physical
examination or ECG occurred.
4 Discussion
The present study is the first to evaluate the steady-state
pharmacokinetic and pharmacodynamic properties of IDeg,
using a 26-h euglycaemic clamp procedure, in elderly
subjects with type 1 diabetes. We report that the ultra-long
pharmacokinetic and pharmacodynamic properties of IDeg
observed in younger adults with type 1 diabetes were the
same in elderly subjects with type 1 diabetes. Accordingly,
the duration of action of IDeg was beyond the clamp
duration of 26 h (end of clamp) in all subjects in both age
groups. In an earlier study in subjects with type 1 diabetes,
the duration of action was reported to be greater than 42 h
[9].
The exposure level of IDeg at steady state was similar in
elderly and younger adult subjects. In both age groups, it
took 2–3 days to reach steady-state exposure, and there-
after the total exposure of IDeg was unchanged from day to
day. As the pharmacokinetic profiles at steady state were
similar between age groups, and the total exposure for the
elderly subjects was comparable to that of the younger
adult group, this suggests that the absorption properties of
IDeg observed in younger adults [5, 6] are preserved in
elderly subjects. The glucose-lowering effect of IDeg at
steady state was numerically lower (but not significantly
different) in elderly subjects versus younger adults, possi-
bly because of the expected decrease in insulin sensitivity
with age [10]. Furthermore, the numerical difference in
effect is likely to be of limited clinical impact given that
insulin is titrated based on individual patient needs. This
finding is in concurrence with recent data from a sub-
analysis of the LIGHT observational study, in which the
glucose-lowering effect of long-acting insulin was lower in
elderly subjects compared with younger subjects [11].
IDeg was well tolerated in younger and elderly subjects
with type 1 diabetes. The incidence of hypoglycaemia in
this trial could be considered artificial to some extent. This
is because a fixed dose level independent of subjects’
individual insulin requirements was applied in this trial, to
be able to compare the pharmacokinetic/pharmacodynamic
response between younger and elderly subjects.
The strengths of this study include the assessment of
both pharmacokinetic and pharmacodynamic properties at
steady state in a once-daily dosing regimen, which is the
most clinically relevant setting. A 6-day dosing period was
used, thereby ensuring that both a pharmacokinetic steady
state and stable glycaemic control were achieved before the
last dose administered during each treatment period. A
further strength of the study is that only subjects with type
1 diabetes were included. This enabled assessment of the
pharmacodynamic response in a euglycaemic glucose
clamp without interference from the effect of endogenous
insulin, which would have been a risk if healthy subjects or
subjects with type 2 diabetes had been included. A
potential limitation of the study was the relatively low
number of subjects included. Large-scale clinical studies to
investigate the efficacy and safety of IDeg in the elderly
population will be able to allow further sub-analyses
evaluating more discrete age ranges.
Although the availability of clinical data regarding the
use of long-acting insulins in elderly subjects is limited [2,
12–15], a number of studies have reported efficacy of such
products in elderly subjects [14] and decreased rates of
hypoglycaemia compared with other treatments [12–16].
Of particular note is a recent meta-analysis comparing
hypoglycaemia rates of IDeg with IGlar in elderly subjects
with type 1 or type 2 diabetes [16]. In this pooled popu-
lation, a numerically lower (by 21 %) rate of overall con-
firmed hypoglycaemia was reported with IDeg compared
with IGlar during the maintenance period, once the optimal
dosage had been determined. Furthermore, nocturnal con-
firmed hypoglycaemia was significantly lower (by 35 %)
with IDeg compared with IGlar [16]. Based on these
results, IDeg could be of particular benefit in elderly
patients, who may have a higher propensity for hypogly-
caemia owing to a higher incidence of co-morbidities and
complications associated with long-standing disease.
In conclusion, the results of the present study show that
the ultra-long and stable pharmacokinetic and pharmaco-
dynamic properties of IDeg observed in younger adults are
52 S. Korsatko et al.
preserved in elderly subjects. These attributes may explain
observations from the earlier meta-analysis in which
elderly subjects had lower rates of hypoglycaemic epi-
sodes, particularly nocturnal episodes, with IDeg [16].
Thus, IDeg is an effective basal insulin treatment for
elderly patients with diabetes.
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